Nikitin et al. further reported that high DMD expression across 134 B-CLL patients was associated with a shorter lymphocyte doubling time and was predictive of a poor patient survival (median overall survival for patients with high DMD expression was 90.1 months vs. median not reached for patients with low DMD expression) [20]. The gene discussed is DMD; the disease is B-cell chronic lymphocytic leukemia.